STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announced today that preliminary findings from a 21-month follow-up analysis of the previously reported successful Phase II type 1 diabetes trial will be presented at the annual ISPAD (International Society for Pediatric and Adolescent Diabetes) meeting in Berlin, Germany, the 26th of September, 2007.
